Business Context and Reporting Period
This Form 8-K, dated March 2, 2026, is a Current Report filed by Home BancShares, Inc. (HOMB) to provide supplemental disclosures regarding its proposed acquisition of Mountain Commerce Bancorp, Inc. (MCBI). The Merger Agreement was originally announced on December 7, 2025. The filing responds to shareholder requests for additional information to avoid transaction delays, specifically updating details on standstill provisions, financial advisor analyses, and prospective financial information.
Key Financial Metrics and Peer Comparisons
The filing does not report Home BancShares' actual historical financial results for a specific period but provides unaudited prospective financial information and peer group comparisons used in the merger valuation.
- Home BancShares (HOMB) Peer Group Data: As of the reporting period, HOMB reported Total Assets of $22,708 million, a Net Interest Margin (NIM) of 4.46%, and a Return on Average Assets (ROAA) of 2.01%. The Tangible Common Equity (TCE) to Risk-Based Capital (RBC) ratio was 18.85%.
- MCBI Peer Group Data: MCBI reported Total Assets of $1,803 million, a NIM of 2.37%, and a ROAA of 0.64%. Its TCE/RBC ratio was 11.99%.
- Valuation Assumptions: Piper Sandler utilized a discount rate of 9.33% for Home common stock and 10.86% for MCBI common stock in Net Present Value analyses.
Material Changes and Updates
The filing updates the previously filed proxy statement/prospectus with the following material changes:
- Standstill Provisions: Clarified that as of March 1, 2026, only one standstill provision from a nondisclosure agreement remains in effect (expiring March 6, 2026). No other companies have approached MCBI regarding a superior proposal since the merger announcement.
- Peer Group Tables: Replaced the "MCBI Peer Group" and "Home Peer Group" tables with updated financial data for comparable companies, including metrics on Nonperforming Assets (NPAs), Commercial Real Estate (CRE) exposure, and profitability ratios.
- Discount Rate Methodology: Disclosed specific inputs for discount rate calculations, including a 4.75% risk-free rate (20-year Treasury) and specific size and industry premiums.
Guidance, Outlook, and Risks
Prospective Financial Information (Home BancShares): The filing includes unaudited prospective financial information provided by Home management to its financial advisor, Hovde Group, LLC. These are not official guidance but were used for fairness opinions.
- 2026 Estimates: Net Interest Income of $916.0 million; Noninterest Income of $188.3 million; Expenses of $466.8 million; EPS of $2.44; Dividends of $0.84 per share.
- 2027 Estimates: Net Interest Income of $944.9 million; Noninterest Income of $196.3 million; Expenses of $483.9 million; EPS of $2.53; Dividends of $0.88 per share.
Transaction Accretion: The merger is projected to be accretive to Home's earnings per share (EPS) and tangible book value per share (TBVPS):
- EPS Accretion: 1.4% at closing, 3.0% in 2026, 3.4% in 2027, and 3.4% in 2028.
- TBVPS Accretion: 0.2% at closing, 0.5% in 2026, 1.0% in 2027, and 1.5% in 2028.
Risks and Contingencies: The filing includes extensive forward-looking statement disclaimers. Key risks include the failure to obtain regulatory or shareholder approvals, integration challenges, potential unknown liabilities of MCBI, changes in interest rates, and the impact of economic conditions on the commercial real estate portfolio. The prospective financial information is explicitly stated not to be financial guidance and involves significant uncertainties.
Investor Verification Checklist
- Verify the final status of the single remaining standstill provision expiring March 6, 2026, and confirm no superior proposals have emerged.
- Review the definitive proxy statement/prospectus (Form S-4) for the full text of the Merger Agreement and detailed risk factors.
- Assess the sensitivity of the projected EPS accretion (1.4% to 3.4%) to changes in interest rates and integration cost assumptions.
- Confirm the accuracy of the unaudited prospective financial information against actual Q4 2025 and Q1 2026 results once reported.
- Monitor regulatory approval timelines, as delays could impact the realization of projected synergies.